Literature DB >> 19890262

Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine.

L Elliot Hong1, Ann Summerfelt, Robert W Buchanan, Patricio O'Donnell, Gunvant K Thaker, Martin A Weiler, Adrienne C Lahti.   

Abstract

Several electrical neural oscillatory abnormalities have been associated with schizophrenia, although the underlying mechanisms of these oscillatory problems are unclear. Animal studies suggest that one of the key mechanisms of neural oscillations is through glutamatergic regulation; therefore, neural oscillations may provide a valuable animal-clinical interface on studying glutamatergic dysfunction in schizophrenia. To identify glutamatergic control of neural oscillation relevant to human subjects, we studied the effects of ketamine, an N-methyl-D-aspartate antagonist that can mimic some clinical aspects of schizophrenia, on auditory-evoked neural oscillations using a paired-click paradigm. This was a double-blind, placebo-controlled, crossover study of ketamine vs saline infusion on 10 healthy subjects. Clinically, infusion of ketamine in subanesthetic dose significantly increased thought disorder, withdrawal-retardation, and dissociative symptoms. Ketamine significantly augmented high-frequency oscillations (gamma band at 40-85 Hz, p=0.006) and reduced low-frequency oscillations (delta band at 1-5 Hz, p<0.001) compared with placebo. Importantly, the combined effect of increased gamma and reduced delta frequency oscillations was significantly associated with more withdrawal-retardation symptoms experienced during ketamine administration (p=0.02). Ketamine also reduced gating of the theta-alpha (5-12 Hz) range oscillation, an effect that mimics previously described deficits in schizophrenia patients and their first-degree relatives. In conclusion, acute ketamine appeared to mimic some aspects of neural oscillatory deficits in schizophrenia, and showed an opposite effect on scalp-recorded gamma vs low-frequency oscillations. These electrical oscillatory indexes of subanesthetic ketamine can be potentially used to cross-examine glutamatergic pharmacological effects in translational animal and human studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890262      PMCID: PMC3055615          DOI: 10.1038/npp.2009.168

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  79 in total

1.  EEG coherence in unmedicated schizophrenic patients: topographical study of predominantly never medicated cases.

Authors:  Y Nagase; Y Okubo; M Matsuura; T Kojima; M Toru
Journal:  Biol Psychiatry       Date:  1992-12-01       Impact factor: 13.382

2.  Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval.

Authors:  H T Nagamoto; L E Adler; M C Waldo; R Freedman
Journal:  Biol Psychiatry       Date:  1989-03-01       Impact factor: 13.382

3.  Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input.

Authors:  P O'Donnell; A A Grace
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

4.  Mid-latency auditory evoked potentials during ketamine anaesthesia in humans.

Authors:  D Schwender; S Klasing; C Madler; E Pöppel; K Peter
Journal:  Br J Anaesth       Date:  1993-11       Impact factor: 9.166

5.  Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation.

Authors:  M A Whittington; R D Traub; J G Jefferys
Journal:  Nature       Date:  1995-02-16       Impact factor: 49.962

6.  Sensory gating in normals and schizophrenics: a failure to find strong P50 suppression in normals.

Authors:  N Kathmann; R R Engel
Journal:  Biol Psychiatry       Date:  1990-06-01       Impact factor: 13.382

7.  Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives.

Authors:  B A Clementz; S R Sponheim; W G Iacono; M Beiser
Journal:  Psychophysiology       Date:  1994-09       Impact factor: 4.016

8.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

9.  Resting EEG in first-episode and chronic schizophrenia.

Authors:  S R Sponheim; B A Clementz; W G Iacono; M Beiser
Journal:  Psychophysiology       Date:  1994-01       Impact factor: 4.016

10.  Computerized EEG in schizophrenia.

Authors:  C N Karson; R Coppola; D G Daniel; D R Weinberger
Journal:  Schizophr Bull       Date:  1988       Impact factor: 9.306

View more
  102 in total

Review 1.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2012-02-21       Impact factor: 9.306

2.  NMDAR antagonist action in thalamus imposes δ oscillations on the hippocampus.

Authors:  Yuchun Zhang; Takashi Yoshida; Donald B Katz; John E Lisman
Journal:  J Neurophysiol       Date:  2012-03-14       Impact factor: 2.714

3.  Ketamine disrupts θ modulation of γ in a computer model of hippocampus.

Authors:  Samuel A Neymotin; Maciej T Lazarewicz; Mohamed Sherif; Diego Contreras; Leif H Finkel; William W Lytton
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

Review 4.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 5.  Scaling brain size, keeping timing: evolutionary preservation of brain rhythms.

Authors:  György Buzsáki; Nikos Logothetis; Wolf Singer
Journal:  Neuron       Date:  2013-10-30       Impact factor: 17.173

6.  Ketamine Alters Outcome-Related Local Field Potentials in Monkey Prefrontal Cortex.

Authors:  Kevin J Skoblenick; Thilo Womelsdorf; Stefan Everling
Journal:  Cereb Cortex       Date:  2015-06-03       Impact factor: 5.357

Review 7.  Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia.

Authors:  Michael J Gandal; J Christopher Edgar; Kerstin Klook; Steven J Siegel
Journal:  Neuropharmacology       Date:  2011-02-22       Impact factor: 5.250

Review 8.  Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective.

Authors:  John H Krystal; Alan Anticevic; Genevieve J Yang; George Dragoi; Naomi R Driesen; Xiao-Jing Wang; John D Murray
Journal:  Biol Psychiatry       Date:  2017-01-13       Impact factor: 13.382

9.  Exposure to Early Life Pain: Long Term Consequences and Contributing Mechanisms.

Authors:  Nicole C Victoria; Anne Z Murphy
Journal:  Curr Opin Behav Sci       Date:  2016-02

10.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.